Summary
Background Adrenal cortical carcinoma (ACC) is a rare cancer with treatment options of limited efficacy, and poor prognosis if metastatic. AT-101 is a more potent inhibitor of B cell lymphoma 2 family apoptosis-related proteins than its racemic form, gossypol, which showed preliminary clinical activity in ACC. We thus evaluated the efficacy of AT-101 in patients with advanced ACC. Methods Patients with histologically confirmed metastatic, recurrent, or primarily unresectable ACC were treated with AT-101 (20 mg/day orally, 21 days out of 28-day cycles) until disease progression and/or prohibitive toxicity. The primary endpoint was objective response rate, wherein a Response Evaluation Criteria In Solid Tumors (RECIST) partial response rate of 25% would be considered promising and 10% not, with a Type I error of 10% and 90% power. In a 2-stage design, 2 responses were required of the first 21 assessable subjects to warrant complete accrual of 44 patients. Secondary endpoints included safety, progression-free survival and overall survival. Results This study accrued 29 patients between 2009 and 2011; median number of cycles was 2. Seven percent experienced grade 4 toxicity including cardiac troponin elevations and hypokalemia. None of the first 21 patients attained RECIST partial response; accordingly, study therapy was deemed ineffective and the trial was permanently closed. Conclusions AT-101 had no meaningful clinical activity in this study in patients with advanced ACC, but demonstrated feasibility of prospective therapeutic clinical trials in this rare cancer.
Similar content being viewed by others
References
Dy BM, Strajina V, Cayo AK et al (2015) Surgical resection of synchronously metastatic adrenocortical cancer. Ann Surg Oncol 22(1):146–151. https://doi.org/10.1245/s10434-014-3944-7
Dy BM, Wise KB, Richards ML et al (2013) Operative intervention for recurrent adrenocortical cancer. Surgery 154(6):1292–1299; discussion 1299. https://doi.org/10.1016/j.surg.2013.06.033
Terzolo M, Angeli A, Fassnacht M et al (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356(23):2372–2380. https://doi.org/10.1056/NEJMoa063360
Berruti A, Terzolo M, Pia A et al (1998) Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of adrenal Cancer. Cancer 83(10):2194–2200
Fassnacht M, Terzolo M, Allolio B et al (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366(23):2189–2197. https://doi.org/10.1056/NEJMoa1200966
Sperone P, Ferrero A, Daffara F et al (2010) Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second−/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer 17(2):445–453. https://doi.org/10.1677/ERC-09-0281
Fassnacht M, Berruti A, Baudin E et al (2015) Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol 16(4):426–435. https://doi.org/10.1016/S1470-2045(15)70081-1
Kroiss M, Quinkler M, Johanssen S et al (2012) Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab 97(10):3495–3503. https://doi.org/10.1210/jc.2012-1419
Ferrari L, Claps M, Grisanti S et al (2016) Systemic therapy in locally advanced or metastatic adrenal cancers: a critical appraisal and clinical trial update. Eur Urol Focus 1(3):298–300. https://doi.org/10.1016/j.euf.2015.06.005
Fassnacht M, Johanssen S, Quinkler M et al (2009) Limited prognostic value of the 2004 International Union against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115(2):243–250. https://doi.org/10.1002/cncr.24030
Fassnacht M, Dekkers O, Else T et al (2018) European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol 179(4):G1–G46. https://doi.org/10.1530/EJE-18-0608
Kirschner LS (2002) Signaling pathways in adrenocortical cancer. Ann N Y Acad Sci 968:222–239
Kanauchi H, Wada N, Clark OH, Duh QY (2002) Apoptosis regulating genes, bcl-2 and bax, and human telomerase reverse transcriptase messenger RNA expression in adrenal tumors: possible diagnostic and prognostic importance. Surgery 132(6):1021–1026; discussion 1026-7. https://doi.org/10.1067/msy.2002.128616
Bushunow P, Reidenberg MM, Wasenko J et al (1999) Gossypol treatment of recurrent adult malignant gliomas. J Neuro-Oncol 43(1):79–86
Flack MR, Pyle RG, Mullen NM et al (1993) Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 76(4):1019–1024. https://doi.org/10.1210/jcem.76.4.8473376
Stein RC, Joseph AE, Matlin SA et al (1992) A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol 30(6):480–482
Investigator’s Brochure (2006) AT-101 [R-(−)-gossypol acetic acid]. Ascenta Therapeutics, Inc. Accessed 31 Mar 2006
Shelley MD, Hartley L, Fish RG et al (1999) Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines. Cancer Lett 135(2):171–180
Liu G, Kelly WK, Wilding G et al (2009) An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 15(9):3172–3176. https://doi.org/10.1158/1078-0432.CCR-08-2985
Heist RS, Fain J, Chinnasami B et al (2010) Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol 5(10):1637–1643. https://doi.org/10.1097/JTO.0b013e3181e8f4dc
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026
Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38(1):143–151
Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181. https://doi.org/10.1016/S1053-4296(03)00031-6
Sharma MR, Stadler WM, Ratain MJ (2011) Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst 103(14):1093–1100. https://doi.org/10.1093/jnci/djr218
Baggstrom MQ, Qi Y, Koczywas M et al (2011) A phase II study of AT-101 (gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol 6(10):1757–1760. https://doi.org/10.1097/JTO.0b013e31822e2941
Ready N, Karaseva NA, Orlov SV et al (2011) Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol 6(4):781–785. https://doi.org/10.1097/JTO.0b013e31820a0ea6
Sonpavde G, Matveev V, Burke JM et al (2012) Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol 23(7):1803–1808. https://doi.org/10.1093/annonc/mdr555
Stein MN, Hussain M, Stadler WM et al (2016) A phase II study of AT-101 to overcome Bcl-2--mediated resistance to androgen deprivation therapy in patients with newly diagnosed castration-sensitive metastatic prostate Cancer. Clin Genitourin Cancer 14(1):22–27. https://doi.org/10.1016/j.clgc.2015.09.010
Swiecicki PL, Bellile E, Sacco AG et al (2016) A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Investig New Drugs 34(4):481–489. https://doi.org/10.1007/s10637-016-0364-5
Kroiss M, Quinkler M, Lutz WK et al (2011) Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol 75(5):585–591. https://doi.org/10.1111/j.1365-2265.2011.04214.x
Almeida MQ, Fragoso MCBV, Lotfi CFP et al (2008) Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J Clin Endocrinol Metab 93(9):3524–3531. https://doi.org/10.1210/jc.2008-0065
Assié G, Letouzé E, Fassnacht M et al (2014) Integrated genomic characterization of adrenocortical carcinoma. Nat Genet 46(6):607–612. https://doi.org/10.1038/ng.2953
Varghese J, Habra MA (2017) Update on adrenocortical carcinoma management and future directions. Curr Opin Endocrinol Diabetes Obes 24(3):208–214. https://doi.org/10.1097/MED.0000000000000332
Zheng S, Cherniack AD, Dewal N et al (2016) Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell 29(5):723–736. https://doi.org/10.1016/j.ccell.2016.04.002
Funding
This study is supported by The Phase 2 Consortium (P2C) through its contract with the National Cancer Institute (N01 CM17104).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Hao Xie declares that he has no conflict of interest. Jun Yin declares that she has no conflict of interest. Manisha H. Shah declares that she has no conflict of interest related to AT-101 except research funding from Bristol-Myers Squibb for a clinical trial in last 2 years. Michael E. Menefee declares that he has no conflict of interest. Keith C. Bible declares that he has no conflict of interest. Diane Reidy-Lagunes declares that she receives research funds from Novartis, Ipsen, and Merck, and is on the advisory board for Novartis, Ipsen, AAA, and Lexicon. Madeleine A. Kane declares that she has no conflict of interest. David I. Quinn declares that he has no conflict of interest. David R. Gandara declares that he has no conflict of interest. Charles Erlichman declares that he has no conflict of interest. Alex A. Adjei declares that he has no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Xie, H., Yin, J., Shah, M.H. et al. A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Invest New Drugs 37, 755–762 (2019). https://doi.org/10.1007/s10637-019-00797-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-019-00797-1